Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sponsors Should Consider Representative Race, Age In Trial Design, US FDA Emphasizes

Executive Summary

A final guidance document from the agency outlines how device sponsors should approach racial, ethnic and age diversity in trial enrollment and data analysis.

You may also be interested in...



Global Medtech Guidance Tracker: September 2017

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-eight new guidance documents were posted to the tracker.

Tips For Recruiting, Reporting Trial Subpopulations In FDA Draft Guidance

FDA instructs device manufacturers and agency staff on its expectations for designing and analyzing trials to reflect outcomes for patient subpopulations, and also provides recruitment tips in a June 20 draft guidance.

Impella Safety Update: Data Supports Pump For Qualified Patients

Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.

Topics

UsernamePublicRestriction

Register

MT121474

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel